Quote:

---

STRAYHORN had been following CYTODYN’s public statements since 2016.

---

It seems she was RPM for leronlimab at the same time she was RPM for Biktarvy. That would seem to be a conflict.

Quote:

---

There were internal discussions within the FDA that CYTODYN, through Amarex, did not provide the FDA “plausible mechanism of action.” STRAYHORN did not think CYTODYN understood how the drug would work.
STRAYHORN received a master’s degree in anatomy from the University of Maryland Dental School.

---

Strayhorn does not seem to have the necessary knowledge to know what blocking CCR5 can do. Therefore she should not opine on what she does not know. Having proposed leronlimab for reduction in inflammation for serious influenza before Cytodyn announced it for possible use in Covid maybe the FDA should have talked to me and I could have set them straight.

Quote:

---

STRAYHORN stated that “it is dangerous to put misinformation and pump up a drug when sick people are dying, relatives are dying…it was a very scary time.”

---

What's dangerous is the FDA crippling a drug trial by not allowing the necessary number of doses for a drug that could have saved lives.

Quote:

---

STRAYHORN was recently diagnosed with cancer and had Googled for information about cancer treatment and “this is not in a setting of a pandemic".

---

If she has a relapse she may regret that Cytodyn was not able to start phase 3 cancer trials sooner.